【摘要】 目的探讨司来吉兰联合复合多巴治疗帕金森病的疗效和安全性。方法将89例帕金森病患者随机分为对照组(45例)和治疗组(44例),对照组患者采用复合多巴等药物治疗,治疗组患者加用司来吉兰治疗,6个月为1个观察周期。于用药前及用药后1、3、6个月采用PD统一评分量表(UPDRS)对两组患者进行疗效评定,并观察其不良反应。结果治疗组患者治疗1个月时与治疗前相比,除UPDRSⅢ评分降低外(P<0.01),UPDRSⅠ、Ⅱ、Ⅳ评分变化均无统计学差异(均P>0.05);治疗3、6个月时与治疗前比较,其UPDRSⅠ～Ⅳ评分均下降(P<0.01);治疗3、6个月时与治疗1个月时比较,UPDRSⅠ、Ⅲ、Ⅳ评分降低均降低(P<0.01,P<0.05);治疗6个月时与治疗3个月时相比,其UPDRSⅠ～Ⅳ评分均无统计学差异(P>0.05)。治疗3、6个月时,治疗组UPDRSⅠ～Ⅳ评分均明显低于对照组(P<0.01,P<0.05)。观察期内,两组患者未出现严重不良反应。结论司来吉兰联用复合多巴可有效改善帕金森病症状,且耐受性好,不良反应少。更多还原

【Abstract】 Objective To investigate the clinical efficacy and safety of selegiline combined with compound levodopa in patients with Parkinson’s disease(PD).Methods By open-label,the patients were divided into two groups:the compound levodopagroup(n=45) and the selegiline plus compound levodopagroup(n=44).The clinical efficacy was assessed with UPDRS 1,3, and 6 months after treatment.Safety data including blood and urine routine tests,blood hepatic and renal function tests,arterial blood pressure and electrocardiogram were recorded and analyzed at the beginning and end of the study.Results In the selegiline plus compound levodopagroup,only UPDRSⅢ score declined significantly(P<0.01)after 1month.After 3 and 6month,UPDRSⅠ-Ⅳ sores all decreased significantly(P<0.01).After treated for 3 and 6 month,UPDRSⅠ,Ⅲ,Ⅳscores decreased statistically(P<0.01,P<0.05)compared with those scores assessed after 1 month.There were no significant differences between the UPDRSⅠ-Ⅳ scores assessed 3 and 6months after treatment(P>0.05).Compared with the compound levodopagroup,UPDRSⅠ-Ⅳ scores declined statistically(P<0.01,P<0.05)after treatment of 3,6 month;UPDRSⅢ scale declined significantly(P<0.01),but UPDRSⅠ,Ⅱ,Ⅳ scales did not declined statistically(all P>0.05)after 1month treatment in the selegiline plus compound levodopagroup.No severe side effect was noted.Conclusions Selegiline combined with compound levodopa in the treatment of PD is effective,safe and well tolerated.更多还原